Maxim Group started coverage on shares of VolitionRX (NYSEAMERICAN:VNRX) in a report published on Monday, TipRanks reports. The firm issued a buy rating and a $8.00 price objective on the medical research company’s stock.
A number of other equities research analysts have also issued reports on the stock. Oppenheimer restated a buy rating and set a $7.00 price target on shares of VolitionRX in a report on Monday, June 1st. Aegis started coverage on shares of VolitionRX in a research note on Wednesday, May 6th. They issued a buy rating and a $10.00 price objective on the stock.
VNRX stock opened at $3.54 on Monday. VolitionRX has a 52-week low of $2.22 and a 52-week high of $6.84.
Institutional investors and hedge funds have recently bought and sold shares of the business. UBS Group AG increased its position in shares of VolitionRX by 196.5% during the 2nd quarter. UBS Group AG now owns 13,338 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 8,839 shares during the last quarter. American International Group Inc. purchased a new position in shares of VolitionRX during the second quarter valued at approximately $56,000. New York State Common Retirement Fund purchased a new position in shares of VolitionRX during the second quarter valued at approximately $95,000. Jane Street Group LLC purchased a new position in shares of VolitionRX during the first quarter valued at approximately $96,000. Finally, Advisor Group Holdings Inc. purchased a new position in shares of VolitionRX during the first quarter valued at approximately $176,000.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Further Reading: How to Invest in Stocks with Increasing Dividends
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.